Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Jiangxi Rimag Group Co., Ltd. Class H ( (HK:2522) ) is now available.
Jiangxi Rimag Group Co., Ltd. has announced two significant connected transactions involving its subsidiary, Rimag Health Management. The company has entered into a Capital Increase Agreement to acquire a 9.58% equity interest in Shanghai Ronggongshe and an Equity Transfer Agreement to purchase a 51% equity interest in Wuhan Ronggongshe. These transactions are part of the company’s strategic efforts to consolidate its holdings and strengthen its market position. The agreements are subject to certain conditions, and stakeholders are advised to exercise caution as the transactions may or may not proceed.
The most recent analyst rating on (HK:2522) stock is a Buy with a HK$21.41 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
More about Jiangxi Rimag Group Co., Ltd. Class H
Average Trading Volume: 4,345,027
Technical Sentiment Signal: Strong Sell
For a thorough assessment of 2522 stock, go to TipRanks’ Stock Analysis page.